– SBFI-26 (SBFI26) is a small molecule inhibitor of epidermal- and brain-specific FABP5 and FABP7 that effectively increases anandamide signaling; dose-dependently reduces mechanical hyperalgesia in vivo, demonstrates significant analgesic and anti-inflammatory properties; also suppresses the malignant progression of castration resistant prostate cancer cells by competitively binding to oncogenic FABP5.